T1	intervention 35 73	Sequential Irinotecan and Flavopiridol
T2	eligibility 453 505	Patients with advanced HCC naÃ¯ve to systemic therapy
T3	outcome-Measure 702 762	improvement in progression-free survival at 4 months (PFS-4)
T4	total-participants 848 850	16
T5	outcome 1016 1021	PFS-4
T7	outcome 1122 1127	SD >1
T8	iv-bin-abs 1116 1117	1
T9	iv-bin-abs 1137 1138	9
T10	outcome 1143 1162	disease progression
T12	outcome 1372 1382	mutant p53
T13	total-participants 1339 1340	9
T14	iv-bin-abs 1366 1367	5
T15	iv-bin-abs 1387 1388	4
T16	outcome 1393 1406	wild-type p53
T6	age 906 914	64 years
T11	outcome 1164 1179	Grade 3 fatigue
T17	outcome 1181 1192	dehydration
T18	outcome 1194 1202	diarrhea
T19	outcome 1204 1237	neutropenia with or without fever
T20	outcome 1239 1250	lymphopenia
T21	outcome 1252 1258	anemia
T22	outcome 1260 1278	hyperbilirubinemia
T23	outcome 1284 1297	transaminitis
